Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia
出版年份 2016 全文链接
标题
Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia
作者
关键词
-
出版物
BRITISH JOURNAL OF HAEMATOLOGY
Volume 175, Issue 4, Pages 641-651
出版商
Wiley
发表日期
2016-11-17
DOI
10.1111/bjh.14285
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Sensitivity of chronic lymphocytic leukemia cells to small targeted therapeutic molecules: An in vitro comparative study
- (2016) Sandra Eketorp Sylvan et al. EXPERIMENTAL HEMATOLOGY
- Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia
- (2016) James S. Blachly et al. SEMINARS IN ONCOLOGY
- Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia
- (2015) J Flynn et al. LEUKEMIA
- Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer
- (2015) Xiu-Xiu Chen et al. Oncotarget
- Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner
- (2015) Shankar Varadarajan et al. Oncotarget
- CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo
- (2015) G P Gregory et al. LEUKEMIA
- Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells
- (2015) Cody Paiva et al. PLoS One
- Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells
- (2014) U. Rozovski et al. BLOOD
- Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma
- (2014) S. K. Kumar et al. BLOOD
- Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients
- (2014) Claire Fabre et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Unknown
- (2014) Amit Mittal et al. MOLECULAR MEDICINE
- Efficacy of Vemurafenib in Hairy-Cell Leukemia
- (2014) Jesvin Samuel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls
- (2013) Martin J. S. Dyer et al. BRITISH JOURNAL OF HAEMATOLOGY
- Molecular Pathways: Targeting the Microenvironment in Chronic Lymphocytic Leukemia—Focus on the B-Cell Receptor
- (2013) Elisa ten Hacken et al. CLINICAL CANCER RESEARCH
- Inhibition of NF- B-Mediated Signaling by the Cyclin-Dependent Kinase Inhibitor CR8 Overcomes Prosurvival Stimuli to Induce Apoptosis in Chronic Lymphocytic Leukemia Cells
- (2013) E. Cosimo et al. CLINICAL CANCER RESEARCH
- Targeted Therapy in Chronic Lymphocytic Leukemia: Past, Present, and Future
- (2013) Alexey V. Danilov CLINICAL THERAPEUTICS
- Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors
- (2013) Håkon Reikvam et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cyclin-dependent kinase inhibitor therapy for hematologic malignancies
- (2013) Prithviraj Bose et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Reprogramming cell death: BCL2 family inhibition in hematological malignancies
- (2013) Lydia Scarfò et al. IMMUNOLOGY LETTERS
- A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
- (2013) John J Nemunaitis et al. Journal of Translational Medicine
- Emerging drug profile: cyclin-dependent kinase inhibitors
- (2013) James S. Blachly et al. LEUKEMIA & LYMPHOMA
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cellular Mechanisms Controlling Caspase Activation and Function
- (2013) A. B. Parrish et al. Cold Spring Harbor Perspectives in Biology
- Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
- (2013) R. Pan et al. Cancer Discovery
- MG132, a proteasome inhibitor, induces apoptosis in tumor cells
- (2012) Na GUO et al. Asia-Pacific Journal of Clinical Oncology
- The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells
- (2012) A J Johnson et al. LEUKEMIA
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
- (2011) S. E. M. Herman et al. BLOOD
- STAT-3 Activates NF- B in Chronic Lymphocytic Leukemia Cells
- (2011) Z. Liu et al. MOLECULAR CANCER RESEARCH
- The Cyclin-Dependent Kinase Inhibitor SCH 727965 (Dinacliclib) Induces the Apoptosis of Osteosarcoma Cells
- (2011) W. Fu et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms of Action of a Dual Cdc7/Cdk9 Kinase Inhibitor against Quiescent and Proliferating CLL Cells
- (2011) A. Natoni et al. MOLECULAR CANCER THERAPEUTICS
- STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells
- (2010) I. Hazan-Halevy et al. BLOOD
- Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
- (2010) David Parry et al. MOLECULAR CANCER THERAPEUTICS
- Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases
- (2010) Kamil Paruch et al. ACS Medicinal Chemistry Letters
- Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer
- (2009) Sergei I. Grivennikov et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers
- (2008) C. Pepper et al. BLOOD
- The NF- B subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target
- (2008) S. Hewamana et al. BLOOD
- Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia
- (2008) M. Vogler et al. BLOOD
- Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy
- (2008) M. Muzio et al. BLOOD
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
- (2008) M. Hallek et al. BLOOD
- The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance
- (2008) M. B. Meads et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now